This gene encodes a member of the subtilisin-like proprotein convertase family, which includes proteases that process protein and peptide precursors trafficking through regulated or constitutive branches of the secretory pathway. The encoded protein undergoes an autocatalytic processing event with its prosegment in the ER and is constitutively secreted as an inactive protease into the extracellular matrix and trans-Golgi network. It is expressed in liver, intestine and kidney tissues and escorts specific receptors for lysosomal degradation. It plays a role in cholesterol and fatty acid metabolism. Mutations in this gene have been associated with autosomal dominant familial hypercholesterolemia. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2014]
Synonyms
PCSK9;proprotein convertase subtilisin/kexin type 9;FH3;PC9;NARC1;LDLCQ1;NARC-1;HCHOLA3;subtilisin/kexin-like protease PC9;neural apoptosis regulated convertase 1;convertase subtilisin/kexin type 9 preproprotein
Pcsk9 involved in several pathways and played different roles in them. We selected most pathways Pcsk9 participated on our site, such as , which may be useful for your reference. Also, other proteins which involved in the same pathway with Pcsk9 were listed below. Creative BioMart supplied nearly all the proteins listed, you can search them on our site.
Pathway Name
Pathway Related Protein
Protein Function
Pcsk9 has several biochemical functions, for example, apolipoprotein binding,apolipoprotein receptor binding,low-density lipoprotein particle binding. Some of the functions are cooperated with other proteins, some of the functions could acted by Pcsk9 itself. We selected most functions Pcsk9 had, and list some proteins which have the same functions with Pcsk9. You can find most of the proteins on our site.
Pcsk9 has direct interactions with proteins and molecules. Those interactions were detected by several methods such as yeast two hybrid, co-IP, pull-down and so on. We selected proteins and molecules interacted with Pcsk9 here. Most of them are supplied by our site. Hope this information will be useful for your research of Pcsk9.
Shapiro, MD; Fazio, S; et al. Targeting PCSK9 for Therapeutic Gains. CURRENT ATHEROSCLEROSIS REPORTS 17:-(2015).
Tavori, H; Giunzioni, I; et al. PCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9. CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY 22:126-132(2015).
We use cookies to understand how you use our site and to improve the overall user experience. This includes
personalizing content and advertising. Read our Privacy Policy
